Share on StockTwits

Marrone Bio Innovations (NASDAQ:MBII) CEO Pamela G. Marrone acquired 1,000 shares of Marrone Bio Innovations stock on the open market in a transaction dated Tuesday, August 12th. The shares were purchased at an average cost of $5.29 per share, for a total transaction of $5,290.00. Following the completion of the transaction, the chief executive officer now directly owns 727,806 shares of the company’s stock, valued at approximately $3,850,094. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

A number of research firms have recently commented on MBII. Analysts at Zacks downgraded shares of Marrone Bio Innovations from an “outperform” rating to a “neutral” rating in a research note on Wednesday, August 13th. They now have a $6.60 price target on the stock. Separately, analysts at Robert W. Baird downgraded shares of Marrone Bio Innovations from an “outperform” rating to a “neutral” rating in a research note on Friday, August 8th. They now have a $12.00 price target on the stock, down previously from $15.00. Finally, analysts at Piper Jaffray downgraded shares of Marrone Bio Innovations from an “overweight” rating to a “neutral” rating in a research note on Friday, August 8th. They now have a $11.00 price target on the stock, down previously from $19.00. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $14.43.

Marrone Bio Innovations (NASDAQ:MBII) opened at 5.79 on Monday. Marrone Bio Innovations has a 1-year low of $5.13 and a 1-year high of $20.00. The stock’s 50-day moving average is $9.3 and its 200-day moving average is $11.90. The company’s market cap is $141.3 million.

Marrone Bio Innovations (NASDAQ:MBII) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.50) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.47) by $0.03. On average, analysts predict that Marrone Bio Innovations will post $-1.77 earnings per share for the current fiscal year.

Marrone Bio Innovations, Inc is a provider of bio-based pest management and plant health products. Bio-based products are consists of naturally occurring microorganisms, such as bacteria and fungi, and plant extracts.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.